King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

King Pharmaceuticals vs. Alpharma

In August 2008, King Pharmaceuticals tried to woo Alpharma with $1.38 billion cash offer. King wasn't prepared to take no for an answer, and it was ready to get hostile if necessary to push the acquisition through.

But Alpharma wasn't as enthusiastic and rejected the offer. Alpharma claimed it had other companies interested in a buyout, but King pushed forward with the hostile bid. King also threatened a proxy battle if Alpharma continued to reject its offers.

Despite Alpharma's repeated objections, a $1.6 billion offer eventually piqued its interest

King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

Suggested Articles

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.

As the election nears, and amid the drumbeat of COVID-19 news, the Trump administration unveiled a new drug pricing initiative.